Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- G Proteins and GPCRs in cancer
- G Proteins and GPCRs as oncogenes: 1980s
- G Proteins and GPCRs as oncogenes: early 1990s
- G Proteins and GPCRs as oncogenes: late 1990s
- G Proteins and GPCRs in tumorigenesis (1)
- G Proteins and GPCRs in tumorigenesis (2)
- G Proteins and GPCRs in tumorigenesis (3)
- The GPCR signaling system
- G proteins and GPCRs in cancer
- GPCRs and metastasis
- GPCRs and tumor-induced angiogenesis
- The onco-GPCRome: a pan-cancer perspective
- The onco-GPCRome: a pan-cancer perspective - orphan GPCRs
- GPCRs: dysregulated but underexploited (1)
- GPCRs: dysregulated but underexploited (2)
- The cancer immunology revolution
- Conclusions
- The team: thank you!
Topics Covered
- G proteins and GPCRs as oncogenes
- G proteins and GPCRs in tumorigenesis
- GPCR signalling
- GPCRs and metastasis
- GPCRs and tumor-induced angiogenesis
- GPCR targeting and immunotherapies
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Gutkind, J.S. (2019, November 28). G proteins and GPCRs in cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 14, 2024, from https://doi.org/10.69645/VDYY9532.Export Citation (RIS)
Publication History
Financial Disclosures
- NIH Intramural, NIDCR/NCI funding, NCI R01 (Tesmer), NCI U54 (Krogan /Ideker), Consultant for: Oncoceutics, Vividion, Domain, Research support from: Kura Oncology and Celldex Therapeutics.
Other Talks in the Series: G Protein-Coupled Receptors (GPCRs) Signaling in Health and Disease
Transcript
Please wait while the transcript is being prepared...
0:00
Hi. I'm Silvio Gutkind.
I'm professor in the Department of Pharmacology and I'm also the Associate Director of
Basic Science at the University of California in the Moores Cancer Center.
So the topic of today is G-proteins and
G-Protein Coupled Receptors called GPCRs in Cancer.
0:18
So G-proteins and G-protein Coupled Receptors are very
familiar to everybody involved in drug discovery.
So these receptors are the largest family
of cell surface molecules involved in signal transmissions,
and are the target of more than 30 percent of all drugs in the market,
and that includes around 50 percent of the top 200 drugs currently being sold.
However, when it comes to cancer with
around 14 million new cases of cancer every year resulting in
roughly eight million deaths each year
worldwide and associated treatment cost of $147 billion,
GPCRs are not really very well investigated in the case of cancer.
So what I will try to explain today is that GPCR are dysregulated but
underexploited particularly in cancer in
this new era of precision medicine in immune oncology.
What I will try to cover today is very specific areas in G-proteins in GPCRs in cancer,
an overview of that topic,
and then some new opportunities and there will be a brief discussion of
that of targeting GPCRs in this new area of cancer immunotherapies.
1:30
So G-Protein Coupled Receptors in cancer has been known for quite some time.
So the reality, the first study was published in 1986 in the,
should I say old days in which you can take tumors,
grind them, isolate DNA,
transfer into fibroblasts, and you can isolate oncogenes based on
the ability to form what we call foci so the cells pile up one on top of each other,
and we can isolate the DNA's in cloned the genes causing transformation.
Those genes or oncogenes are usually those were highly represented for example,
ras, tyrosine kinases, and so on so forth.
So many of these typical oncogenes that we know are quite important in cancer.
One of them in the wigglier slab encoded a G-Protein Coupled Receptors.
So basically, the sequence revealed that it
was likely to encode a G-Protein Coupled Receptor.
However, something very interesting is that most of the ones I prefer
to for example Ras as a typical oncogene in many cancers,
pancreatic cancer, colon cancer and so on and so forth,
the majority of these oncogenes have mutations.
So it's very easy to grasp the mutations in
these molecules may lead to aberrant proliferation in cancer.
In the case of the Mas oncogene however,
there were no mutations in the coding sequence which to
some extent suggested that other the expression itself
can cause cancer or we really didn't have at
that time a real perspective of how they came about.
So in our words, should I say embraced by the community as a very prominent oncogene,
and to some extent that may have been neglected for quite some time.